C12N 2770/28123
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2770/28123 (Virus like particles [vlp]) appears on 12 US grants and 17 published applications in this corpus.
Search patents in C12N- Granted patents
- 12
- Published applications
- 17
- Assignees
- 15
- Inventors
- 36
- Latest grant
- 25 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 3 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 3 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 0 |
| 2014 | 2 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 2 |
| 2017 | 1 | 1 |
| 2018 | 1 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 2 |
| 2022 | 1 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
| 2026 | 0 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Virus-like nanoparticles for oral delivery25 Feb 2025US 12,234,260 B2The Regents of the University of California
- Virus-like nanoparticles for oral delivery11 Oct 2022US 11,466,055 B2The Regents of the University of California
- Chemically activated nanocapsid functionalized for cancer targeting21 Aug 2018US 10,053,494 B2The Regents of the University of California
- Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector2 May 2017US 9,637,524 B2The Regents of the University of California
- Multiple antigen delivery system using hepatitis E virus-like particle9 Dec 2014US 8,906,862 B2National Institute of Infectious Disease
- Hepatitis e virus-like particles (vlps) derived from consensus sequences10 Sep 2026US 2026/0263379 A1Novo Capsid Technologies LLC
- A Fusion Protein and a Particulate Antigen Containing the Same27 Aug 2026US 2026/0250328 A1Xiamen Innovax Biotech Co., Ltd.
- Methods and compositions of quaternary immunomodulatory nanoparticles for medical applications and immunotherapy25 Jun 2026US 2026/0174841 A1
- Virus-like nanocapsid for oral delivery of insulin11 Jun 2026US 2026/0159817 A1The Regents of the University of California
- 2019-ncov (sars-cov-2) vaccine4 Apr 2024US 2024/0108715 A1Vaxbio Ltd
Most cited
By later US patents
- Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines8US 6,287,759 B1The United States of America as represented by the Department of Health and Human Services · 2001
- Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector4US 8,906,863 B2The Regents of the University of California · 2014
- Multiple antigen delivery system using hepatitis E virus-like particle2US 8,906,862 B2National Institute of Infectious Disease · 2014
- Virus-like nanoparticles for oral delivery1US 11,466,055 B2The Regents of the University of California · 2022
- Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines1US 6,207,416 B1The United States of America as represented by the Department of Health and Human Services · 2001